Impact of timing of adjuvant chemothapy for early breast cancer: the Royal Marsden Hospital experience.

Background: The optimal time to deliver adjuvant chemotherapy has not been defined.

Methods: A retrospective study of consecutive patients receiving adjuvant anthracycline and/or taxane 1993-2010. Primary endpoint included 5-year disease-free survival (DFS) in patients commencing chemotherapy <31 versus ≥31 days after surgery.